IN8bio, Inc. (INAB) Stock Analysis & Investment Frameworks
IN8bio, Inc. (INAB) stock analysis on Invetso. Review IN8bio, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
IN8bio, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
IN8bio, Inc. Key Financial Metrics
- Market Cap: $9.13M
- Revenue: $N/A
- ROE: -93.66%
- ROIC: -115.70%
- Dividend Yield: N/A
About IN8bio, Inc.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
IN8bio, Inc. Investment Frameworks
Invetso analyzes IN8bio, Inc. (INAB) across the following frameworks:
- IN8bio, Inc. 10Y Growth Potential
- IN8bio, Inc. Scenario Analysis
- IN8bio, Inc. Risks & Opportunities
- IN8bio, Inc. Economic Moat
- IN8bio, Inc. Business Model
- IN8bio, Inc. Management
- IN8bio, Inc. SWOT Analysis
- IN8bio, Inc. Porter's 5 Forces
- IN8bio, Inc. PESTLE Analysis
- IN8bio, Inc. ESG Analysis